Effect of rhBNP on Coronary Microcirculation in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 160
- 主要终点
- MVO/LV(%)
研究概览
简要总结
The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI
详细描述
Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PPCI within 24 hours of symptom onset
- •Target vessel QFR-MR>250mm Hg*s/m
排除标准
- •claustrophobia
- •Postoperative TIMI grade 0-1
- •Pregnancy
研究组 & 干预措施
Experimental Group 1
The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).
干预措施: recombinant human B-type natriuretic peptide (Drug)
结局指标
主要结局
MVO/LV(%)
时间窗: 3-14 days after PPCI
Microvascular obstruction assessed by magnetic resonance imaging
次要结局
- MVO/LV(%)(30±7 days after PPCI)
- MACCEs(7days,30days,3months,6 months)
- LVEDV(ml)(3-14 days and 90±7 days after PPCI)
- Troponin (highest value)(3-14 days after PPCI)
- LGE/LV(%)(3-14 days and 90±7 days after PPCI)
- IMH(3-14 days after PPCI)
- LVESV(ml)(3-14 days and 90±7 days after PPCI)
